Filing Details

Accession Number:
0001615219-15-000089
Form Type:
4
Zero Holdings:
No
Publication Time:
2015-12-01 12:17:27
Reporting Period:
2015-11-30
Filing Date:
2015-12-01
Accepted Time:
2015-12-01 12:17:27
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1615219 Flex Pharma Inc. FLKS Pharmaceutical Preparations (2834) 465087339
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1291961 H Christoph Westphal C/O Flex Pharma, Inc.
800 Boylston Street
Boston MA 02199
President And Ceo Yes Yes Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2015-11-30 887 $12.32 3,923,414 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 2,697,264 Indirect By Longwood Fund II. L.P.
Footnotes
  1. The purchase reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted on February 17, 2015.
  2. Longwood Fund II GP, LLC is the ultimate General Partner of Longwood Fund II, L.P. Christoph Westphal, M.D., Ph.D., Richard Aldrich and Michelle Dipp, M.D., Ph.D. (collectively, the "Managers") are managers of Longwood Fund II GP, LLC, and, as such, may be deemed to have shared voting and dispositive power with respect to the issuer's securities held by Longwood Fund II, L.P. (the "Longwood Shares"). Each of the Managers disclaims beneficial ownership of the Longwood Shares, except to the extent of their respective pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the shares for purposes of Section 16 or for any other purpose.